Microbot Medical (MBOT) Liabilities and Shareholders Equity (2010 - 2026)

Microbot Medical (MBOT) has 17 years of Liabilities and Shareholders Equity data on file, last reported at $78.1 million in Q1 2026.

• For the quarter ending Q1 2026, Liabilities and Shareholders Equity rose 152.71% year-over-year to $78.1 million; the trailing twelve-month figure through Mar 2026 stood at $274.5 million (up 453.82% YoY), and the FY2025 full-year result was $81.5 million, up 1252.08% from the prior year.
• Liabilities and Shareholders Equity for Q1 2026 stood at $78.1 million, down from $81.5 million in the prior quarter.
• Across five years, Liabilities and Shareholders Equity topped out at $81.8 million in Q3 2025 and bottomed at $5.2 million in Q3 2024.
• The 5-year median for Liabilities and Shareholders Equity is $9.5 million (2022), against an average of $23.9 million.
• The widest annual swing landed in 2022, when Liabilities and Shareholders Equity plunged 62.39%; it then soared 1469.89% in 2025.
• A 5-year view of Liabilities and Shareholders Equity shows it stood at $9.5 million in 2022, then slipped by 12.69% to $8.3 million in 2023, then retreated by 27.57% to $6.0 million in 2024, then soared by 1252.08% to $81.5 million in 2025, then retreated by 4.27% to $78.1 million in 2026.
• The last three Liabilities and Shareholders Equity figures came in at $78.1 million (Q1 2026), $81.5 million (Q4 2025), and $81.8 million (Q3 2025), per Business Quant data.

Peer Comparison